Milestone Scientific, Inc.

As of June 30, 2026, Milestone Scientific, Inc. carries a market capitalization of 28.49M, placing it among publicly traded companies globally. Its enterprise value stands at 27.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Milestone Scientific, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Milestone Scientific, Inc. has 88.76M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.90, and the price-to-book ratio stands at 8.21.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 27.04M versus a market cap of 28.49M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Milestone Scientific, Inc. maintains a current ratio of 1.85, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Milestone Scientific, Inc. posted a negative return on equity (ROE) of -121.67, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -50.54, reflecting losses generated across the asset base. The company generates approximately 607,817.23 in revenue per employee across its workforce of 15.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.80 indicates how many times Milestone Scientific, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Milestone Scientific, Inc.'s stock has declined approximately 27.89% over the past 52 weeks. The 50-day moving average sits at 0.42, while the 200-day moving average is 0.35.

Over the twelve months ended June 30, 2026, Milestone Scientific, Inc. generated 9.42M in revenue and converted that into -4.14M in net income, yielding earnings per share of -0.05. EBITDA reached -3.92M, while operating income came in at -4.10M.

As of June 30, 2026, Milestone Scientific, Inc. holds 2.07M in cash and equivalents against 615,703.00 in total debt, resulting in a net debt position of -1.60M. Total book value stands at 3.47M, with working capital of 3.72M providing operational flexibility.

Milestone Scientific, Inc. produced -642,639.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -15,119.00 in capital expenditures, free cash flow totaled -657,758.00 - equivalent to -0.01 per share.

Over the twelve months ended June 30, 2026, Milestone Scientific, Inc. posted a gross margin of 70.23, reflecting its pricing power and cost economics. The operating margin of -43.56 and net profit margin of -43.98 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.40: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.09, meaning Milestone Scientific, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Milestone Scientific, Inc.'s most recent stock split took place on January 14, 2004 with a 3:1 split ratio.

As of June 30, 2026, Milestone Scientific, Inc. has an Altman Z-Score of -19.33, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.